Published in J Sex Med on July 16, 2013
Risks and benefits of late onset hypogonadism treatment: an expert opinion. World J Mens Health (2013) 1.01
Circulating total testosterone and PSA concentrations in a nationally representative sample of men without a diagnosis of prostate cancer. Prostate (2015) 0.90
Testosterone Therapy in Men With Prostate Cancer. Eur Urol (2015) 0.85
Testosterone and benign prostatic hyperplasia. Asian J Androl (2015) 0.82
Testosterone therapy in men with prostate cancer: literature review, clinical experience, and recommendations. Asian J Androl (2015) 0.80
Clinical correlates of enlarged prostate size in subjects with sexual dysfunction. Asian J Androl (2014) 0.78
Testosterone Therapy Among Prostate Cancer Survivors. Sex Med Rev (2016) 0.77
Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories. Cancer Med (2016) 0.77
Urban rural comparisons of polycystic ovary syndrome burden among adolescent girls in a hospital setting in India. Biomed Res Int (2015) 0.75
Testosterone deficiency in the aging male. Ther Adv Urol (2016) 0.75
Male accessory gland infection: relevance of serum total testosterone levels. Int J Endocrinol (2014) 0.75
Association between Serum Testosterone and PSA Levels in Middle-Aged Healthy Men from the General Population. Curr Urol (2017) 0.75
Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med (2010) 6.13
Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab (2008) 3.67
Association of hypogonadism with vitamin D status: the European Male Ageing Study. Eur J Endocrinol (2011) 2.28
Low diastolic ambulatory blood pressure is associated with greater all-cause mortality in older patients with hypertension. J Am Geriatr Soc (2009) 2.28
BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur Urol (2005) 2.26
Definitions/epidemiology/risk factors for sexual dysfunction. J Sex Med (2010) 2.17
Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab (2010) 2.01
Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn (2011) 1.93
Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU Int (2014) 1.73
Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum. Eur Urol (2004) 1.72
Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction. Eur Urol (2006) 1.70
A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment-a systematic review. Eur Urol (2013) 1.70
The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol (2012) 1.68
PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. Prostate (2013) 1.67
IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J Sex Med (2012) 1.66
Comparison of serum testosterone and estradiol measurements in 3174 European men using platform immunoassay and mass spectrometry; relevance for the diagnostics in aging men. Eur J Endocrinol (2012) 1.65
Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol (2011) 1.60
Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care (2010) 1.60
Low prolactin is associated with sexual dysfunction and psychological or metabolic disturbances in middle-aged and elderly men: the European Male Aging Study (EMAS). J Sex Med (2013) 1.59
DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther (2011) 1.59
Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care (2011) 1.58
Frailty and sexual health in older European men. J Gerontol A Biol Sci Med Sci (2012) 1.58
Frailty in relation to variations in hormone levels of the hypothalamic-pituitary-testicular axis in older men: results from the European male aging study. J Am Geriatr Soc (2011) 1.57
Sulphonylureas and cancer: a case-control study. Acta Diabetol (2008) 1.56
Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med (2010) 1.54
The relationships between sex hormones and sexual function in middle-aged and older European men. J Clin Endocrinol Metab (2011) 1.53
Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab (2009) 1.53
Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin (2011) 1.48
Management of acute myocardial infarction in the real world: a summary report from The Ami-Florence Italian Registry. Intern Emerg Med (2008) 1.48
Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev (2006) 1.47
The effect of statin therapy on testosterone levels in subjects consulting for erectile dysfunction. J Sex Med (2010) 1.46
Depression as a risk factor for diabetes: a meta-analysis of longitudinal studies. J Clin Psychiatry (2013) 1.45
Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf (2014) 1.44
Association between 25-hydroxyvitamin D levels and cognitive performance in middle-aged and older European men. J Neurol Neurosurg Psychiatry (2009) 1.44
Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism (2008) 1.43
Summary of the recommendations on sexual dysfunctions in men. J Sex Med (2010) 1.42
Determinants of testosterone recovery after bariatric surgery: is it only a matter of reduction of body mass index? Fertil Steril (2013) 1.41
Perceived ejaculate volume reduction in patients with erectile dysfunction: psychobiologic correlates. J Androl (2010) 1.41
Elevated levels of gonadotrophins but not sex steroids are associated with musculoskeletal pain in middle-aged and older European men. Pain (2011) 1.41
Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care (2008) 1.33
The European Male Ageing Study (EMAS): design, methods and recruitment. Int J Androl (2008) 1.33
Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care (2007) 1.32
Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med (2009) 1.32
Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol (2009) 1.32
Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol (2009) 1.30
Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract (2008) 1.30
Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS). J Sex Med (2009) 1.28
Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med (2011) 1.28
Vardenafil can improve continence recovery after bilateral nerve sparing prostatectomy: results of a randomized, double blind, placebo-controlled pilot study. J Sex Med (2009) 1.27
Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol (2011) 1.26
Functional differences in visceral and subcutaneous fat pads originate from differences in the adipose stem cell. PLoS One (2012) 1.25
Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: a meta-analysis. Acta Diabetol (2009) 1.25
Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology (2004) 1.25
Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract (2007) 1.23
Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care (2010) 1.22
Human bladder as a novel target for vitamin D receptor ligands. J Clin Endocrinol Metab (2004) 1.22
Development and validation of a 6-item version of the female sexual function index (FSFI) as a diagnostic tool for female sexual dysfunction. J Sex Med (2009) 1.22
Partial AZFc deletions and duplications: clinical correlates in the Italian population. Hum Genet (2008) 1.21
Increased estrogen rather than decreased androgen action is associated with longer androgen receptor CAG repeats. J Clin Endocrinol Metab (2008) 1.19
The ability of three different models of frailty to predict all-cause mortality: results from the European Male Aging Study (EMAS). Arch Gerontol Geriatr (2013) 1.18
Multicenter study on the prevalence of sexual symptoms in male hypo- and hyperthyroid patients. J Clin Endocrinol Metab (2005) 1.18
Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. J Endocrinol (2011) 1.16
Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology (2006) 1.15